TY - JOUR AU - Bergethon, K. AU - Shaw, A. T. AU - Ou, S. H. PY - 2012 DA - 2012// TI - ROS1 rearrangements define a unique molecular class of lung cancers JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.35.6345 DO - 10.1200/JCO.2011.35.6345 ID - Bergethon2012 ER - TY - JOUR AU - Yoneda, K. Y. AU - Scranton, J. R. AU - Michael, A. PY - 2015 DA - 2015// TI - Interstitial lung disease associated with Crizotinib in patients with advanced none small cell lung Cancer: independent review of four PROFILE trials JO - Clin Lung Cancer VL - 18 UR - https://doi.org/10.1016/j.cllc.2017.03.004 DO - 10.1016/j.cllc.2017.03.004 ID - Yoneda2015 ER - TY - STD TI - Data on file (62a). Pfizer. ID - ref3 ER - TY - JOUR AU - Shaw, A. T. AU - Ou, S. -. H. I. AU - Bang, Y. -. J. PY - 2014 DA - 2014// TI - Crizotinib in ROS1-rearranged non–small-cell lung Cancer JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406766 DO - 10.1056/NEJMoa1406766 ID - Shaw2014 ER - TY - STD TI - Gemma A, Kusumoto M, Kurihara Y, et al. Analysis of Data on Interstitial Lung Disease Onset and Its Risk Following Treatment of ALK-positive NSCLC with Xalkori [poster]. Presented at WCLC 2017, October 15–18; Yokohama, Japan. Abstract no. 9146. ID - ref5 ER - TY - JOUR AU - Créquit, P. AU - Wislez, M. AU - Fleury Feith, J. PY - 2015 DA - 2015// TI - Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000577 DO - 10.1097/JTO.0000000000000577 ID - Créquit2015 ER - TY - JOUR AU - Tamiya, A. AU - Okamoto, S. AU - Miyazaki, M. AU - Shimizu, S. AU - Kitaichi, M. AU - Nakagawa, K. PY - 2013 DA - 2013// TI - Severe acute interstitial lung disease after Crizotinib therapy in a patient with EML4-ALKepositive none-small-cell lung cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.3730 DO - 10.1200/JCO.2012.43.3730 ID - Tamiya2013 ER - TY - JOUR AU - Tachihara, M. AU - Kobayashi, K. AU - Ishikawa, Y. PY - 2014 DA - 2014// TI - Successful Crizotinib Rechallenge after Crizotinib-induced interstitial lung disease JO - Jpn J Clin Oncol VL - 44 UR - https://doi.org/10.1093/jjco/hyu074 DO - 10.1093/jjco/hyu074 ID - Tachihara2014 ER - TY - JOUR AU - Rimkunas, V. M. AU - Crosby, K. E. AU - Li, D. PY - 2012 DA - 2012// TI - Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-3351 DO - 10.1158/1078-0432.CCR-11-3351 ID - Rimkunas2012 ER - TY - JOUR AU - Wiesweg, M. AU - Eberhardt, W. E. AU - Reis, H. PY - 2017 DA - 2017// TI - High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.08.137 DO - 10.1016/j.jtho.2016.08.137 ID - Wiesweg2017 ER - TY - JOUR AU - Lin, J. J. AU - Ritterhouse, L. L. AU - Ali, S. M. PY - 2017 DA - 2017// TI - ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.01.004 DO - 10.1016/j.jtho.2017.01.004 ID - Lin2017 ER - TY - JOUR AU - Davies, K. D. AU - Mahale, S. AU - Astling, D. P. PY - 2013 DA - 2013// TI - Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0082236 DO - 10.1371/journal.pone.0082236 ID - Davies2013 ER - TY - JOUR AU - Vaishnavi, A. AU - Schubert, L. AU - Rix, U. PY - 2017 DA - 2017// TI - EGFR mediates responses to small-molecule drugs targeting oncogenic fusion kinases JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-17-0109 DO - 10.1158/0008-5472.CAN-17-0109 ID - Vaishnavi2017 ER -